Multiple myeloma, a malignant tumor of plasma cells (terminally differentiated B-lymphocytes), is the second-most common hematologic malignancy in adults and accounts for approximately 2% of cancer deaths.1,2 The cancer is treatable but not curable, although the introduction of newer drugs has prolonged survival, and chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen shows further promise.3 This evidence concerns the gene TNFRSF17 and cancer.